Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection

Senhwa Biosciences, Inc. announced that Taiwan Food and Drug Administration has approved its Phase II IND application of Silmitasertib to treat patients with community-acquired pneumonia caused by...

Related Keywords

National Taiwan University ,T Ai Pei ,Taiwan ,National Taiwan University Hospital ,Modcs Bourayne ,National Taiwan University Cancer Center ,Ministry Of Health ,Drug Administration ,Senhwa Biosciences Inc ,Senhwa Biosciences ,Taiwan Food ,Far Eastern Memorial Hospital ,Tri Service General Hospital ,Taoyuan General Hospital ,Markets ,